Xin Lang Cai Jing·2025-10-28 12:35Core Viewpoint - Kanglong Chemical plans to acquire 82.54% of Wuxi Baiaode Biotechnology Co., enhancing its capabilities in structure-based drug discovery and protein science services [1][2]. Group 1: Acquisition Details - The acquisition is expected to significantly enhance Kanglong Chemical's technical platform and service capabilities in structural biology, complex drug target protein preparation, and analysis [1]. - The transaction is subject to customary closing conditions and aims to improve the company's integrated service platform for global biopharmaceutical clients [1][2]. Group 2: Baiaode's Strengths - Baiaode is a leading CRO in structural biology, providing one-stop solutions from gene to protein structure analysis, which supports clients in advancing structure-based drug discovery projects [2]. - The company has established significant technical advantages in complex drug target protein preparation, extensive X-ray protein crystallization, and advanced cryo-electron microscopy structure analysis [2]. - Baiaode has developed a bio-computing platform that integrates structure with AI/ML, creating a closed-loop optimization system for new drug development [2]. Group 3: Synergies and Future Prospects - The acquisition will enhance Kanglong Chemical's service capabilities in protein preparation, biological function analysis, compound screening, protein crystallization, and structure analysis, creating synergies with existing business segments [2]. - Kanglong Chemical's integrated platform will empower Baiaode in client resources, operational efficiency, and AI technology applications, maximizing the collaborative value of the acquisition [2][3]. - Both companies' leadership expressed optimism about the collaboration, highlighting the potential for Baiaode to reach more global clients and enhance its business capabilities [3].